Abstract:Alcohol-associated hepatitis (AH) is associated with increased short-term mortality in the presence of infections and rapid onset of extrahepatic organ failure driven by intestinal dysbiosis. [ 1 ] Deleterious modifications of the gut microbiota (GM) which include bacteria, fungi, and viral groups in the presence of alcohol are well documented across multiple studies globally. [ 2 ] Gut microbiota contributes to individual susceptibility to alcohol-related liver disease (ALD) and AH through detrimental changes to immune signaling, functional metabolism, and the gut–brain axis. [ 3 ] Specific bacterial taxa have been shown to affect the promotion, progression, and clinical events associated with ALD and AH. For example, in the presence of alcohol, pathogenic bacteria, such as Acinetobacter baumannii enhance their virulence. Alcohol use reduces bacterial diversity, decreases the abundance of beneficial Bacteroidetes, and increases that of pathogenic Proteobacteria, as demonstrated by a significant decrease in Ruminococcaceae and an increase in both Lachnospiraceae and Enterobacteriaceae. [ 4 , 5 ] Alcohol-induced GM dysbiosis leads to liver damage owing to the proliferation of harmful microorganisms that produce exotoxins. One such exotoxin, cytolysin, secreted by Enterococcus faecalis , can directly harm hepatocytes. A higher presence of cytolysin-positive Enterococcus faecalis correlates with greater severity of liver disease and elevated mortality rates in patients with AH. [ 6 ] Specific GM, their interactions, and metabolites are associated with complications of AH and the corresponding treatment outcomes. [ 7 ] Similarly, fungal dysbiosis and fungal metabolites affect the severity of AH. The burgeoning field of research on fungal dysbiosis and proliferation of specific fungal species in ALD has revealed significant findings. Elevated serum levels of anti- Saccharomyces cerevisiae immunoglobulin G antibodies, which indicate a systemic immune response to fungi and their byproducts, are observed in patients with alcohol use disorder and ALD. In patients with AH, heightened serum anti- Saccharomyces cerevisiae immunoglobulin G antibodies levels are associated with increased mortality. Additionally, a higher relative abundance of specific fungal species, such as Candida albicans and Malassezia restricta in the gut, correlates with more severe liver injury and increased mortality in ALD patients. [ 8–10 ] Preliminary studies have shown that patients with ALD and AH can benefit from GM modulation. Clinical trials have explored the use of fecal microbiota transplantation (FMT) to alter the gut microbiome of patients with AH. Studies have demonstrated that AH patients who received FMT from healthy donors exhibited lower rates of alcohol relapse, infections, or hospitalizations; higher rates of resolution of hepatic encephalopathy and ascites; and improved survival in both the short and long term when compared to standard medical care, including pentoxifylline therapy. [ 11–13 ] Another randomized controlled study included 120 patients with AH who received either prednisolone or a healthy donor FMT. Patients receiving FMT had better 90-day survival rates and a reduced incidence of infections compared to those receiving prednisolone. [ 14 ] Probiotics have been shown to improve clinical outcomes in alcohol-associated cirrhosis, and foundational evidence supports their positive effects on GM. Preliminary evidence also supports the beneficial effects of probiotic therapy on GM in AH. [ 15 , 16 ] Nonetheless, the validated and replicated benefits of probiotic therapy and their impact on survival in the context of GM modulation remain unknown. Similarly, probiotic therapy-related modifications within fungal communities, fungal–bacterial interactions, and associated clinical outcomes in AH are enigmatic. We aimed to study the clinical outcomes and GM changes in AH patients receiving high-dose probiotic infusion (HDPI) compared to corticosteroid therapy (CST). Additionally, survival outcomes compared with matched patients undergoing healthy donor FMT were also analyzed. We also studied mycobiome (fungal) community changes and their interactions among patients with AH in the context of HDPI and CST therapies.

Impact of a Single Dose of a Probiotic Nutritional Supplement (AB001) on Absorption of Ethylalcohol: Results From a Randomized Double-Blind Crossover Study

Chronic Uptake of A Probiotic Nutritional Supplement (AB001) Inhibits Absorption of Ethylalcohol in the Intestine Tract – Results from a Randomized Double-blind Crossover Study

Regulation of Alcohol and Acetaldehyde Metabolism by a Mixture of Lactobacillus and Bifidobacterium Species in Human

Effects of multi-species probiotic supplementation on alcohol metabolism in rats

Diet High in Alcohol Impacts the Gut Microbiota and Associated Metabolome (P08-134-19)

Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice

Preclinical Evaluation of Sodium Butyrate's Potential to Reduce Alcohol Consumption: A Dose-Escalation Study in C57BL/6J Mice in Antibiotic-Enhanced Binge-Like Drinking Model

Effectiveness of genetic feedback on alcohol metabolism to reduce alcohol consumption in young adults: an open-label randomized controlled trial

Research protocol of the efficacy of probiotics for the treatment of alcohol use disorder among adult males: A comparison with placebo and acceptance and commitment therapy in a randomized controlled trial

Ketone Supplementation Dampens Subjective and Objective Responses to Alcohol: Evidence From a Preclinical Rat Study and a Randomized, Cross-Over Trial in Healthy Volunteers

Effect of the Consumption of Alcohol-Free Beers with Different Carbohydrate Composition on Postprandial Metabolic Response

Clinical efficacy of probiotics in the treatment of alcoholic liver disease: a systematic review and meta-analysis

Effect of probiotics Lactobacillus paracasei GKS6, L. plantarum GKM3, and L. rhamnosus GKLC1 on alleviating alcohol-induced alcoholic liver disease in a mouse model

Intake of Lactobacillus rhamnosus GG (LGG) fermented milk before drinking alcohol reduces acetaldehyde levels and duration of flushing in drinkers with wild-type and heterozygous mutant ALDH2: a randomized, blinded crossover controlled trial

Probiotics—role in alleviating the impact of alcohol liver disease and alcohol deaddiction: a systematic review

Probenecid as a pharmacotherapy for alcohol use disorder: A randomized placebo‐controlled alcohol interaction trial

Clinical outcomes and associated bacterial and fungal microbiota changes after high dose probiotic therapy for severe alcohol-associated hepatitis: An observational study

The biphasic effects of moderate alcohol consumption with a meal on ambiance-induced mood and autonomic nervous system balance: a randomized crossover trial

Randomized Placebo-Controlled Clinical Trial of Dutasteride for Reducing Heavy Drinking in Men

Probiotics-Based Treatment as an Integral Approach for Alcohol Use Disorder in Alcoholic Liver Disease

A Compound Containing Aldehyde Dehydrogenase Relieves the Effects of Alcohol Consumption and Hangover Symptoms in Healthy Men: An Open-Labeled Comparative Study